Table 6. Studies about surgical resection for rectal GIST.
| Year | Country | Center | TA: NTA (cases) | Tumor size (cm) | Pre-IM treatment, n (%) | Recurrence and metastasis, n (%) | DFS (TA vs. NTA or total) | OS (TA vs. NTA or total) |
|---|---|---|---|---|---|---|---|---|
| 2004 (23) | Korea | Single | 13:29 | 4.5 vs. 7.2 | 0 | 27 (64.3) | 92.3%±7.4% vs. 92.1%±9.2% (2-year DFS, P=0.98) | 100% vs. 91.0%±6.1% (2-year OS, P=0.25) |
| 2007 (13) | China | Single | 13:16 | 2.9 vs. 7.9 | – | 12 (41.4) | 58.6% (5-year DFS) | 82.8% (5-year OS) |
| 2013 (14) | Netherlands | Multi | 2:30 | 5.5 (average) | 22 (68.8) | 13 (40.6) | 78.1% (3-year DFS) | 93.8% (3-year OS) |
| 2013 (24) | China | Single | 5:16 | 7.5±6.4 | 0 | 15 (71.4) | 33% (5-year DFS) | 46% (5-year OS) |
| 2014 (15) | China | Single | 8:13 | 3.7±2.3 vs. 7.0±3.2 | 5 (23.8) | 7 (33.3) | 95.2±6.6 vs. 34.9±8.7 months, P=0.006 | 46% (5-year OS) |
| 2015 (11) | UK | Single | 2:11 | 7.6 (mean) | 9 (81.8) | 2 (15.3) | 38 (range, 20–129) months | 62 (range, 39–162) months |
| 2017 (16) | USA | Single | 23:24 | 4.5 (average) | 17 (36.2) | 27 (57.4) | 31.9% (5-year DFS) | 55.3% (5-year OS) |
| 2017 (25) | USA | Multi | 163:168 | 2.5 vs. 6.2 | 59 (17.7) | – | – | 80.1% vs. 74.1% (5-year OS, P=0.04) |
GIST, gastrointestinal stromal tumor; TA, transanal; NTA, nontransanal; Pre-IM, preoperative imatinib treatment; DFS, disease-free survival; OS, overall survival.